Evidence map›Paper›PMID 35571429›Full record

ArticleAnnals of translational medicine2022

An N

Danjun Song, Yingming Tian, Jun Luo, Guoliang Shao, Jiaping Zheng

Abstract read
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Danjun Song *Department of Interventional Therapy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Yingming Tian *Department of Interventional Therapy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Jun Luo *Department of Interventional Therapy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Guoliang ShaoDepartment of Interventional Therapy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Jiaping ZhengDepartment of Interventional Therapy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) is the leading cause of tumor-related mortality worldwide. N Methods: We used Pearson's correlation coefficient (r) to identify m6A-associated lncRNAs. We then performed univariate, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analyses on the screened m6A-related lncRNAs to build a prognostic risk model for patients with HCC. The prognostic values and predictive performance of the model were then analyzed through Kaplan-Meier curve, receiver operating characteristic (ROC) curve, and nomogram. In addition, the potential value of this model for assessing sorafenib or immunotherapeutic responses was investigated based on the R package "pRRophetic" and immunophenoscore (IPS), respectively. Results: Fourteen m6A-related lncRNAs were identified to construct the predictive model (P<0.05). Patients with high risk showed poorer survival than those with low risk. The risk score may serve as an independent predictor for the prognosis of patients with HCC even in the subgroup analysis. Moreover, our predictive model outperformed Conclusions: This study identified that a novel 14-m6A-related lncRNA signature could be a promising predictor for patient survival, and it might provide a vista for treatment response assessment of chemotherapy and immunotherapy.

Indexed as

Hepatocellular carcinoma (HCC)immunotherapylong noncoding RNAs (lncRNAs)N6-methyladenosine (m6A)

Identifiers

PMID35571429
PMCPMC9096396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.